J. Safra Sarasin Holding AG cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 244,877 shares of the medical research company's stock after selling 26,882 shares during the quarter. Amgen comprises approximately 1.1% of J. Safra Sarasin Holding AG's holdings, making the stock its 28th largest holding. J. Safra Sarasin Holding AG's holdings in Amgen were worth $63,825,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of the stock. Talbot Financial LLC grew its holdings in Amgen by 5.6% during the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after acquiring an additional 2,274 shares in the last quarter. Asset Advisors Investment Management LLC increased its stake in Amgen by 9.0% during the 3rd quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after purchasing an additional 2,954 shares in the last quarter. Ascent Wealth Partners LLC lifted its holdings in shares of Amgen by 0.7% during the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after purchasing an additional 64 shares during the period. Principal Financial Group Inc. lifted its stake in Amgen by 6.0% during the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock valued at $204,659,000 after acquiring an additional 35,785 shares during the period. Finally, ICICI Prudential Asset Management Co Ltd boosted its holdings in Amgen by 242.2% in the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock valued at $6,255,000 after purchasing an additional 16,985 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.
Insider Activity at Amgen
In related news, EVP Murdo Gordon sold 8,771 shares of the company's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares in the company, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 in the last three months. Corporate insiders own 0.69% of the company's stock.
Amgen Trading Up 0.4 %
NASDAQ AMGN traded up $1.00 on Friday, hitting $280.84. 1,994,531 shares of the stock were exchanged, compared to its average volume of 2,790,190. The company has a market capitalization of $150.99 billion, a price-to-earnings ratio of 37.20, a P/E/G ratio of 2.63 and a beta of 0.59. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company's 50-day moving average price is $301.52 and its two-hundred day moving average price is $292.83.
Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.39%. Amgen's payout ratio is presently 126.09%.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. Morgan Stanley lifted their target price on shares of Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Truist Financial cut their price target on shares of Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. Piper Sandler upped their price objective on shares of Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Bank of America raised their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Finally, Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Amgen currently has an average rating of "Hold" and an average price target of $310.57.
Check Out Our Latest Report on Amgen
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
